Resource Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer Graphical

[1]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[2]  Xianming Deng,et al.  Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2. , 2017, Cancer cell.

[3]  H. Ditzel,et al.  Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC , 2017, Journal of the National Cancer Institute.

[4]  Matthew V. Holt,et al.  The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity , 2016, Cell.

[5]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[6]  Stefano Piccolo,et al.  YAP/TAZ at the Roots of Cancer. , 2016, Cancer cell.

[7]  Julia B. Cordero,et al.  Integrin signalling regulates YAP and TAZ to control skin homeostasis , 2016, Journal of Cell Science.

[8]  S. Antonarakis,et al.  Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma , 2016, Nature Genetics.

[9]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[10]  Jennifer B Dennison,et al.  Functional annotation of rare gene aberration drivers of pancreatic cancer , 2016, Nature Communications.

[11]  Bin Zhao,et al.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer , 2015, Cell.

[12]  G. G. Galli,et al.  YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. , 2015, Molecular cell.

[13]  K. Guan,et al.  YAP and TAZ: a nexus for Hippo signaling and beyond. , 2015, Trends in cell biology.

[14]  Antonio Rosato,et al.  Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth , 2015, Nature Cell Biology.

[15]  I. Clay,et al.  YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers , 2015, PLoS genetics.

[16]  Benjamin J. Raphael,et al.  CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer , 2015, Genome Biology.

[17]  P. Nelson,et al.  ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. , 2015, Cancer cell.

[18]  Randy L. Johnson,et al.  Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ. , 2015, Cell reports.

[19]  N. Tapon,et al.  The Hippo pathway promotes cell survival in response to chemical stress , 2015, Cell Death and Differentiation.

[20]  Antonio Marchetti,et al.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies , 2015, Nature Genetics.

[21]  Jian Sun,et al.  Genetic landscape of esophageal squamous cell carcinoma , 2014, Nature Genetics.

[22]  Jonathan A. Cooper,et al.  Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. , 2014, Cancer cell.

[23]  Shan Jiang,et al.  Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer , 2014, Cell.

[24]  Patrick Cahan,et al.  Hippo Pathway Activity Influences Liver Cell Fate , 2014, Cell.

[25]  Joseph Rosenbluh,et al.  KRAS and YAP1 Converge to Regulate EMT and Tumor Survival , 2014, Cell.

[26]  Prahlad T. Ram,et al.  A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.

[27]  Daniel T. Montoro,et al.  Tumor‐propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis , 2014, The EMBO journal.

[28]  H. Ji,et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.

[29]  G. Halder,et al.  The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment , 2013, Nature Reviews Drug Discovery.

[30]  David M. Thomas,et al.  The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.

[31]  K. Guan,et al.  The Hippo pathway: regulators and regulations. , 2013, Genes & development.

[32]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[33]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[34]  D. Pan,et al.  The hippo signaling pathway in development and cancer. , 2010, Developmental cell.

[35]  C. Kim,et al.  NF‐κB activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression , 2010, Journal of cellular physiology.

[36]  Jeannie T. Lee,et al.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. , 2009, Cancer cell.

[37]  M. Sudol,et al.  Mst2 and Lats Kinases Regulate Apoptotic Function of Yes Kinase-associated Protein (YAP)* , 2008, Journal of Biological Chemistry.

[38]  B. Wang,et al.  The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. , 2008, Developmental cell.

[39]  Zhengyu Zha,et al.  TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway , 2008, Molecular and Cellular Biology.

[40]  R. Jaenisch,et al.  YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.

[41]  Li Li,et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.

[42]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[43]  R. Fehon,et al.  Delineation of a Fat tumor suppressor pathway , 2006, Nature Genetics.

[44]  Jianmin Zhang,et al.  Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.

[45]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[47]  D. Haber,et al.  salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines , 2002, Cell.

[48]  S. Jhanwar,et al.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Minna,et al.  Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. , 1995, Cancer research.

[50]  L. Chin,et al.  Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. , 2016, Cancer discovery.

[51]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .